Form 4: Merck Executive DeLuca Acquires Shares Post-Performance Payout

Merck & Co. EVP Richard R. DeLuca acquired 12,264 shares of common stock at $107.4 per share following the satisfaction of performance criteria for his performance share units.

Summary

• Richard R. DeLuca, EVP & President of Merck Animal Health, acquired 12,264 shares of Merck & Co., Inc. common stock.
• The transaction occurred on January 26, 2026, at a price of $107.4 per share.
• This acquisition resulted from the distribution of net after-tax shares upon the satisfaction of performance criteria for performance share units granted on March 31, 2023.
• The performance shares were paid out at 94 percent of the target awards.
• The payout includes dividends accrued over a three-year performance period, which concluded on December 31, 2025.
• Following this transaction, DeLuca directly beneficially owns 197,858.834 shares of common stock.
• Additionally, DeLuca indirectly owns 1,312.5134 shares through the Merck U.S. Savings Plan (401(k)), including shares and dividends earned through January 8, 2026.

Sentiment

Score: 7

Explanation: The filing indicates that performance criteria were largely met, leading to an executive share acquisition. This is generally positive as it shows management alignment and successful execution against goals, though not at 100% of target.

Positives

• The executive's acquisition of shares demonstrates continued alignment of management interests with shareholder interests.
• The payout of performance share units indicates that the company met specific performance criteria over the three-year period ending December 31, 2025.

Negatives

• Performance shares were paid out at 94 percent of target awards, indicating that not all maximum performance criteria were met.

Future Outlook

NA

Management Comments

• The transaction reflects the distribution of shares upon the satisfaction of performance criteria for performance share units, indicating the achievement of specific corporate goals.

Industry Context

Executive compensation tied to performance share units is a common practice in the pharmaceutical and animal health industries, aiming to align executive incentives with long-term company performance and shareholder value creation. This type of transaction is a standard component of executive remuneration packages designed to retain key talent and motivate performance.

Comparison to Industry Standards

• Executive compensation structures, including performance share units with multi-year vesting and performance periods, are standard across large-cap pharmaceutical companies like Pfizer, Johnson & Johnson, and Novartis. The payout at 94% of target suggests a strong, but not exceptional, performance against predefined metrics, which is typical for well-managed companies in a competitive industry.
• The inclusion of dividend reinvestment and 401(k) plan holdings in beneficial ownership reporting is also a standard practice, reflecting comprehensive disclosure of executive equity holdings.

Stakeholder Impact

• Shareholders: The acquisition of shares by a key executive, resulting from performance-based compensation, generally signals management's confidence in the company's future and aligns their interests with those of shareholders. The payout at 94% of target suggests solid, though not perfect, performance.

Key Dates

Keywords

Merck, MRK, Insider Transaction, Form 4, Executive Compensation, Stock Acquisition, Performance Shares, Pharmaceuticals, Animal Health